Generic Name |
Brand Name/ Alternative Name |
Expression System |
Manufacturer |
R&D Stage |
Human insulin, recombinant |
Novolin R, NN-729, Novolin R, Actrapid, Velosulin BR, 诺和灵, ヒトインスリン(遺伝子組換え) |
Yeast (Saccharomyces cerevisiae)
|
Novo Nordisk |
Approval |
Human insulin isophane |
Novolin N, Insulatard, Protaphane |
Yeast (Saccharomyces cerevisiae)
|
Novo Nordisk |
Approval |
Human insulin, zinc suspension |
Monotard, Ultratard |
Yeast (Saccharomyces cerevisiae)
|
Novo Nordisk |
Approval |
Insulin aspart |
NovoLog, NovoRapid, Fiasp, 诺和锐 |
Yeast (Saccharomyces cerevisiae)
|
Novo Nordisk |
Approval |
insulin aspart protamine + insulin aspart |
Biphasic insulin aspart, NovoMix, NovoLog Mix 50/50, 70/30 |
Yeast (Saccharomyces cerevisiae)
|
Novo Nordisk |
Approval |
insulin degludec |
Tresiba, IDeg, 诺和达, トレシーバ |
Yeast (Saccharomyces cerevisiae)
|
Novo Nordisk |
Approval |
Insulin degludec+Liraglutide |
IDegLira, Tresiba, Insulin degludec/Victoza,诺和益, ゾルトファイ |
Yeast (Saccharomyces cerevisiae)
|
Novo Nordisk |
Approval |
Insulin detemir |
Levemir, レベミル, 诺和平 |
Yeast (Saccharomyces cerevisiae)
|
Novo Nordisk |
Approval |
Insulin Degludec+Insulin Aspart |
DegludecPlus, Ryzodeg 70/30, IDegAsp, NN1045,诺和佳 |
Yeast (Saccharomyces cerevisiae)
|
Novo Nordisk |
Approval |
Recombinant human insulin |
Humulin R, 优泌林 |
Escherichia coli (E. coli) |
Eli Lilly, Genentech |
Approval |
Human insulin isophane |
Humulin N |
Escherichia coli (E. coli) |
Eli Lilly |
Approval |
Lispro Insulin |
Humalog, Liprolog, 优泌乐, ルムジェブ |
Escherichia coli (E. coli) |
Eli Lilly |
Approval |
lispro+protamine insulin |
Humalog Mix, Liprolog Mix, 优泌乐 |
Escherichia coli (E. coli) |
Eli Lilly |
Approval |
Glargine Insulin |
Basagla, Rezvoglar, Abasaglar, インスリン グラルギン(遺伝子組換え) |
Escherichia coli (E. coli) |
Eli Lilly |
Approval |
Recombinant human insulin |
Afrezza, Insuman |
Escherichia coli (E. coli) |
Sanofi |
Approval |
Insulin lispro |
Admelog, SAR342434 |
Escherichia coli (E. coli) |
Sanofi |
Approval |
Insulin glargine |
Lantus, Toujeo, 来得时 |
Escherichia coli (E. coli) |
Sanofi |
Approval |
Insulin Glargine+Lixisenatide |
Suliqua 100/33, Glargine Insulin-recombination, Synthesis of Lixisenatide |
N.A. |
Sanofi, Genzyme, Zealand Pharma |
Approval |
insulin glulisine |
Apidra |
Escherichia coli (E. coli) |
Sanofi, LifeScan |
Approval |
Human isophane insulin |
Rinsulin Mix 30/70, Rinsulin NPH |
Pending update |
Geropharm |
Approval |
Insulin Glargine |
Lusduna |
Escherichia coli (E. coli) |
Merck |
Approval, Withdrawn |
Insulin aspart |
Pending update |
Pending update |
Geropharm |
Approval |
Insulin human inhalation powder |
Afresa, Afrezza, Insulin, Insulin human, Insulin human (inhalation powder), Insulin inhalation, Technosphere Insulin, SAR-439065, Technosphere Insulin System |
E. coli (K12) |
MannKind Corporation, Sanofi |
Approval |
Glargine Insulin |
Pending update |
Pending update |
PT Kalbe Farma |
Approval |
Glargine Insulin |
bGlargine, Semglee |
Yeast (Pichia Pastoris) |
Viatris, Biocon Group, Mylan |
Approval |
Insulin aspart |
bAspart |
Yeast (Pichia Pastoris) |
Viatris, Mylan, Biocon Group |
Approval |
Human insulin, recombinant |
Inpremzia |
Yeast (Pichia Pastoris) |
Baxter, CELERITY PHARMS |
Approval |
Glargine Insulin, biosimilar |
Pending update |
Yeast (Pichia Pastoris) |
HEC, Lannett |
Approval |
lispro+protamine insulin |
速秀霖® 25 |
Pending update |
Ganlee |
Approval |
Insulin aspart |
锐秀霖 |
Pending update |
Ganlee, Sandoz |
Approval |
Lispro Insulin |
速秀霖 |
Pending update |
Ganlee, Sandoz |
Approval |
Glargine Insulin |
长秀霖 |
Pending update |
Ganlee, Sandoz |
Approval |
Human insulin, recombinant |
Pending update |
Pending update |
Hefei Tianmai Biotechnology Development Co., Ltd. |
Approval |
Lispro Insulin |
Pending update |
Pending update |
Wanbang Biopharma |
Approval |
Human insulin, recombinant |
Pending update |
Pending update |
Wanbang Biopharma |
Approval |
Glargine Insulin |
Pending update |
Pending update |
Wanbang Biopharma, Fosun Pharma |
Approval |
Human insulin, recombinant |
优思灵 |
Pichia Pastoris |
The United Laboratories International Holdings Limited (TUL) |
Approval |
Glargine Insulin |
Pending update |
Pending update |
MSD, Samsung Bioepis |
Approval |
Insulin aspart |
锐舒霖 |
Pending update |
Tonghua Dongbao Pharmaceutical |
Approval |
Glargine Insulin |
Glargine insulin biosimilars (THTB), 平舒霖 |
Pending update |
Tonghua Dongbao Pharmaceutical |
Approval |
Recombinant human insulin |
Pending update |
Pending update |
Tonghua Dongbao Pharmaceutical |
Approval |
Glargine Insulin |
Pending update |
Pending update |
WOCKHARDT |
Approval |
mecasermin |
INCRELEX |
Escherichia coli |
IPSEN, Genentech, Tercica |
Approval |
Insulin aspart |
Pending update |
Pending update |
Zhejiang Hisun Pharmaceutical Co., Ltd |
Approval |
Glargine Insulin |
Pending update |
Escherichia coli |
Chongqing Fujin, Lunan Pharmaceutical |
Approval |
Insulin aspart |
优倍灵 |
Yeast |
The United Laboratories International Holdings Limited (TUL) |
Approval |
Glargine Insulin |
优乐灵 |
Pending update |
The United Laboratories International Holdings Limited (TUL) |
Approval |
Insulin prandial injectable |
Linjeta, VIAject |
Pending update |
Albireo Pharma, Biodel |
Submit for approval |
Insulin Lispro |
GP40191 |
Pending update |
Geropharm |
Submit for approval |
Insulin glargine |
GP40201 |
Pending update |
Geropharm |
Submit for approval |
insulin |
Biosimilar |
Pending update |
Marvel Lifesciences Ltd |
Submit for approval |
Insulin+Protamine Insulin |
Biosimilar |
Pending update |
HEC |
Submit for approval |
Glargine Insulin |
Biosimilar |
Pending update |
Hefei Tianmai Biotechnology |
Submit for approval |
insulin degludec |
Biosimilar |
Pending update |
Jilin Jinsheng, Huisheng Pharm, Hainan Sihuan Pharmaceutical, PEG-BIO Biopharm |
Submit for approval |
lispro+protamine insulin |
Biosimilar |
Pending update |
Wanbang Biopharma, Fosun Pharma |
Submit for approval |
insulin lispro |
LY900014 |
Pending update |
Eli Lilly |
Submit for approval |
Glargine Insulin |
Biosimilar |
Pending update |
Liaoning Boao Bio Pharmaceutical, Lepu Medicdal |
Submit for approval |
Insulin aspart |
Biosimilar |
Pending update |
Hainan Sihuan Pharmaceutical, Huisheng Pharm |
Submit for approval |
insulin aspart protamine + insulin aspart |
Biosimilar |
Pending update |
Hainan Sihuan Pharmaceutical, Huisheng Pharm |
Submit for approval |
insulin degludec |
Biosimilar |
Pending update |
Hainan Sihuan Pharmaceutical, Huisheng Pharm |
Submit for approval |
Insulin aspart |
Biosimilar |
Pending update |
Hainan Sihuan Pharmaceutical, Huisheng Pharm |
Submit for approval |
Icodec Insulin/NN9535 |
Pending update |
Pending update |
Novo Nordisk |
Phase III |
Insulin icodec |
IA287, qw Preparation |
Yeast |
Novo Nordisk |
Phase III |
Basal insulin-Fc |
Basal insulin-Fc, BIF, LY-3209590, LY 3209590, LY3209590 |
CHO cell |
Eli Lilly and Company |
Phase III |
Insulin glargine |
HOE901-U300 |
Pending update |
Sanofi |
Phase III |
Exubera |
Inhalated insulin, delisted |
Pending update |
Pfizer, Sanofi, Nektar Therapeutics |
Phase III |
Insulin tregopil |
Pending update |
Pending update |
Biocon Group |
Phase III |
ELGN-2112 |
Pending update |
Pending update |
Elgan Pharma |
Phase III |
ELGN-2112 |
Pending update |
Pending update |
Elgan Pharma |
Phase III |
Oral spray insulin |
Pending update |
Pending update |
Generex Biotechnology |
Phase III |
insulin |
Pending update |
Pending update |
MannKind Corporation |
Phase III |
Subetta |
adrugcontaining released-active forms of antibodies to the insulin receptor β-subunit and antibodies to endothelial nitric oxide synthase |
Pending update |
Materia Medica Holding |
Phase III |
Oral Insulin-NTRA-2112 |
Oral |
Pending update |
Nutrinia |
Phase III |
Intranasal Insulin |
Pending update |
Pending update |
Panamerican University |
Phase III |
insulin aspart protamine + insulin aspart |
Pending update |
Pending update |
SL Pharm |
Phase III |
insulin degludec |
Pending update |
Pending update |
HEC |
Phase III |
Insulin Degludec+Insulin Aspart |
Pending update |
Pending update |
HEC |
Phase III |
Insulin Degludec+Insulin Aspart |
Pending update |
Pending update |
Huisheng Pharm, Hainan Sihuan Pharmaceutical Co., ltd |
Phase III |
insulin aspart protamine + insulin aspart |
Pending update |
Pending update |
Jilin JINsheng |
Phase III |
INS068 |
Pending update |
Pending update |
Jiangsu Hengrui Pharmaceuticals , Luzsana Biotechnology, Chengdu Shengdi |
Phase III |
insulin |
Pending update |
Pending update |
Merck, Merck Sharp & Dohme |
Phase III |
insulin degludec |
Pending update |
Pending update |
Bovaxbio, Chenan Biopharm |
Phase III |
Insulin Degludec+Insulin Aspart |
Pending update |
Pending update |
Hainan Sihuan Pharmaceutical Co., ltd, Huisheng Pharm |
Phase III |
Insulin+Protamine Insulin |
Pending update |
Pending update |
Hainan Sihuan Pharmaceutical Co., ltd, Huisheng Pharm |
Phase III |
Protamine Insulin |
Pending update |
Pending update |
Hainan Sihuan Pharmaceutical, Huisheng Pharm |
Phase III |
lispro+protamine insulin |
Pending update |
Pending update |
Tonghua Dongbao Pharmaceutical |
Phase III |
BC Lispro-THDB0206 |
Ultra-Rapid-Acting BC Lispro |
Pending update |
Tonghua Dongbao Pharmaceutical, Adocia |
Phase III |
Insulin enteric-coated pills |
Pending update |
Pending update |
FOSSE BIO, Tsinghua University |
Phase III |
Oral Insulin-ORMD-0801 |
Oral insulin-ORMD-0801 (PODTM) |
Pending update |
Oramed Pharmaceuticals |
Phase III |
Human insulin |
Pending update |
Pending update |
Zhejiang Hisun Pharmaceutical Co., Ltd |
Phase III |
Glargine Insulin |
Pending update |
Pending update |
Zhejiang Hisun Pharmaceutical Co., Ltd |
Phase III |
insulin degludec |
Pending update |
Pending update |
CTTQ Pharma |
Phase III |
insulin degludec |
Pending update |
Pending update |
The United Laboratories International Holdings Limited (TUL) |
Phase III |
Insulin intranasal |
Intranasal insulin |
Pending update |
Adhera Therapeutics, MDRNA |
Phase II |
Insulin Lispro+Pramlintide |
Compound-Omit |
Pending update |
Adocia |
Phase II |
insulin Inhaled-AER 501 |
Inhaled insulin |
Pending update |
Aerami Therapeutics |
Phase II |
BIOD-123 |
New formulation, Rapid-onset |
Pending update |
Albireo Pharma, Biodel |
Phase II |
intranasal insulin |
Intranasal insulin |
Pending update |
Biocon Group, Cpex Pharmaceuticals |
Phase II |
HDV Insulin Lispro |
Preparation |
Pending update |
Diasome Pharmaceuticals |
Phase II |
Lispro-PH20 |
Subcutaneous drug delivery |
Pending update |
Halozyme Therapeutics |
Phase II |
Aspart-PH20 |
Pending update |
Pending update |
Halozyme Therapeutics |
Phase II |
Insulin338 |
Oral insulin |
Pending update |
Merrion Pharmaceuticals, Novo Nordisk |
Phase II |
Oral insulin |
Oral |
Pending update |
Oshadi Drug Administration |
Phase II |
Super-Long-Acting Basal Insulin-PE0139 |
Super-Long-Acting, fusion protein |
Pending update |
PhaseBio Pharmaceuticals |
Phase II |
Pramlintide+ insulin |
XP3924 |
Pending update |
Xeris Pharmaceuticals |
Phase II |
BMS-754807 |
Pending update |
Pending update |
Bristol Myers Squibb |
Phase II |
Compound:基础长效胰岛素+GLP-1 |
HR17031 |
Pending update |
Jiangsu Hengrui Pharmaceuticals Co., Ltd |
Phase II |
Insulin Glargine+Insulin Lispro |
BC Combo THDB 0207, BioChaperone Combo |
Pending update |
Tonghua Dongbao Pharmaceutical Co., Ltd, Adocia |
Phase II |